Cell-based assays to help speed toxicity studies
January 25, 2012Research and Development Qiagen, cell-based assays, drug discovery
Use of cell-based assay technology is set to grow rapidly over the next decade, helping to speed up drug discovery …
Roche launches $5.7 billion hostile bid for Illumina
January 25, 2012Research and Development, Sales and Marketing Diagnostics, Illumina, Roche
Roche has launched a hostile takeover bid for US diagnostics company Illumina. The Swiss manufacturer appears tired of waiting for …
Premier Research appoints Etienne Drouet as executive director, Oncology Europe
January 25, 2012Business Services, Research and Development, Sales and Marketing Etienne Drouet, Premier Research
Premier Research Group has announced the appointment of Etienne Drouet to the position of executive director, Oncology Europe.In this position, …
Gates urges investment in innovations for developing nations
January 25, 2012Research and Development AIDS, Bill Gates, Global Fund, TB, malaria
Bill Gates has called on global leaders to invest in innovations that are accelerating progress against poverty, or risk a …
Councils given £2.2 billion for public health
January 25, 2012Research and Development, Sales and Marketing Lansley, NHS, public health outcomes framework
The government’s new vision for public health has come under fire from observers worried that accountability for the strategy remains …
MHRA Inspections of CROs
January 24, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Audits, Wainwright Associates, inspectons
In accordance with the provisions of the new pharmacovigilance legislation, as per Directive 2010/84/EU, EU Competent Authorities may inspect the …
Moving towards milestones: the evolving pharma – biotech relationship
January 24, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Deals, Susan Aldridge, biotech, pharma
Big pharma is going through the greatest ever wave of patent expiries, while small biotechs are finding it hard to …
Richard Barker elected to Celgene’s board of directors
January 24, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Celgene, Richard Barker
Celgene, the biopharma firm specialising in cancer and inflammatory diseases, has elected Richard Barker to its board of directors. Dr …
Genzyme’s Framingham site cleared by FDA
January 24, 2012Manufacturing and Production FDA, Fabrazyme, Fabry, Genzyme
The FDA has cleared Genzyme to begin production of Fabrazyme at its new manufacturing site. The approval of the new …
Patheon gets bigger in softgels with Procaps alliance
January 24, 2012Manufacturing and Production Patheon, Procaps, manufacturing
Contract development and manufacturing organisation Patheon has stepped up its position in the market for pharmaceutical capsules with the signing …
Alnylam cuts workforce by a third
January 23, 2012Research and Development, Sales and Marketing Alnylam, Novartis, job cuts, rnai
Alnylam will cut 33% of its workforce this year as it looks to focus on developing its own products. The …
MPs to criticise NHS reforms
January 23, 2012Sales and Marketing Clegg, Dorrell, NHS reform, health bill
Reform of the NHS is risking its financial stability and the care of the elderly, according to MPs. The concerns …
Carbogen Amcis buys French CRO
January 23, 2012Manufacturing and Production Carbogen Amcis, Creapharm Parenterals
Swiss contract manufacturing organisation Carbogen Amcis has acquired a contract manufacturer based in France – Creapharm Parenterals – to bolster …
Contract research news in brief
January 23, 2012Research and Development CoreLab Partners and Acurian, Quintiles, vivoPharma
Quintiles invests in new biomarket firm and sets up a new office in China, plus updates from vivoPharma, CoreLab Partners …
Merck pays $37m to settle Canadian Vioxx claims
January 23, 2012Sales and Marketing Canada, Merck, Vioxx
Merck will pay a maximum of C$37 million to settle all claims against its painkiller Vioxx in Canada. The settlement …
Genzyme lifted by EU approval of Fabrazyme facility
January 20, 2012Manufacturing and Production Boston, EMA, Fabrazyme, Genzyme
Sanofi subsidiary Genzyme moved a crucial step closer to resolving its long-standing manufacturing problems after the European Medicines Agency gave …
Payment changes of authority’s fees in France
January 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates, regulatory affairs
Changes are being made in the way fees are paid for regulatory submissions and procedures in France. Fees are no …
Novartis’ Signifor recommended in Europe
January 20, 2012Research and Development, Sales and Marketing CHMP, Cushing's disease, Novartis, Signifor
A European committee has recommended Novartis’ Signifor for the treatment of a rare, debilitating endocrine disorder. The European Committee for …
EMA to review safety of MS drug Gilenya
January 20, 2012Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya
The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …
British pharmacy to sell ‘smart pills’
January 20, 2012Sales and Marketing Lloyds pharmacy, Proteus Biomedical, smart pill
Proteus Biomedical has teamed up with Lloydspharmacy to sell Helius, a smart pill that tells a patient when to take …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
